KOSDAQChemicals036670

Samyang KCI

₩4,970▲ 1.64%2026-11-18 close
Market Cap
₩53.5B
Turnover
₩24,180,430
Volume
4.9K
Shares out.
10.8M
PER
6.0×
PBR
0.4×
EPS
₩817
Dividend Yield
5.10%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩250 per share · Prices as of the 2026-11-18 close

01

Report overview

Export-led personal care ingredients maker faces profit volatility

Samyang KCI is an export-heavy personal care ingredient maker whose Q3 2026 operating profit rose 189.3% year on year, yet its 2025 full-year operating profit remained below the 2022 level.

  1. 1

    Revenue rose 6.0% to KRW 116.8 billion in 2025, the largest of 2022–2025, while operating profit fell 27.5% to KRW 10.9 billion.

  2. 2

    Operating profit reached KRW 3.82 billion in Q2 2026, up 83.8% from the prior quarter, and Q3 operating profit of KRW 3.24 billion rose 189.3% from a year earlier.

  3. 3

    Operating cash flow turned negative at -KRW 894 million in 2025, after KRW 24.3 billion in 2024.

  4. 4

    Press reports put exports at about 83% of revenue in the first half of 2025, indicating high dependence on overseas customers.

  5. 5

    In March 2026 the board approved cancelling 509,800 treasury shares, with an planned cancellation amount of about KRW 4.2 billion.

02

Business structure

Samyang KCI is a personal care ingredient maker that produces functional raw materials used in everyday products such as shampoos and conditioners.

Its core products are polymers used in shampoo and surfactants used in conditioners, and according to an company information site, the sales mix is surfactants 55.80%, polymers 28.11%, other products 14.18%, and other merchandise 1.91%.

Because surfactant sales are the largest revenue source, earnings are highly sensitive to the selling prices and demand for this product line.

A credit rating report published in May 2025 described the company as holding the second position in the global cationic surfactant market, and noted that the market is small in size but competition is relatively low.

At In-Cosmetics Global in April 2025, the company showcased the Encapguard series, which disperses high-content ceramides in water, and emphasized that it can be applied in powder form across various formulations.

At the show, its technical staff discussed application methods and usage concentrations with R&D teams of global brands. Press reports said exports accounted for KRW 50.4 billion of the KRW 60.4 billion in first-half 2025 revenue, about 83%, which indicates a customer base tilted heavily overseas.

The joint booth with Verdant, which joined the Samyang Group in 2023, shows the group pairing ingredient technologies in customer proposals. Samyang Corporation became the largest shareholder in 2017, and in April 2025 the company renamed itself from KCI to Samyang KCI as part of group brand integration. Its production sites are reported to be the Daesan plant in Chungnam Seosan and the Siheung plant.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩28.7B₩1.1B3.9%
2025Q4₩27.8B₩2.1B7.6%
2026Q1₩29.9B₩2.1B6.9%
2026Q2₩35.5B₩3.8B10.8%
2026Q3₩33.9B₩3.2B9.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩109.6B₩21.9B₩17.8B20.0%18.1%25.4%
2023₩109.9B₩10.3B₩11B9.3%10.3%12.1%
2024₩110.2B₩15B₩14.7B13.6%12.4%14.9%
2025₩116.8B₩10.9B₩9.7B9.3%7.8%14.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Based on disclosed annual results, revenue went from KRW 109.6 billion in 2022 to KRW 109.9 billion in 2023 (up 0.3%), KRW 110.2 billion in 2024 (up 0.2%) and KRW 116.8 billion in 2025 (up 6.0%), rising for three consecutive years from 2023 to 2025.

Among 2022–2025, 2025 was the largest year for revenue and 2022 was the smallest. Operating profit was KRW 21.9 billion in 2022, KRW 10.3 billion in 2023 (down 53.0%), KRW 15 billion in 2024 (up 46.2%) and KRW 10.9 billion in 2025 (down 27.5%), with 2022 the largest year and 2023 the smallest.

The operating margin fell from 20.0% in 2022 to 9.3% in 2023, recovered to 13.6% in 2024, and dropped back to 9.3% in 2025. Revenue grew while margins compressed, so the roles of raw material costs and product mix changes merit close review.

Net profit attributable to controlling shareholders went from KRW 17.8 billion in 2022 to KRW 11 billion in 2023, KRW 14.7 billion in 2024 and KRW 9.74 billion in 2025, a 33.8% decline in 2025.

Net income including non-controlling interests was reported at the same amounts as controlling shareholder net profit in every year from 2022 to 2025. Operating cash flow rose from KRW 13 billion in 2022 to KRW 19.1 billion in 2023 and KRW 24.3 billion in 2024, then turned to -KRW 894 million in 2025.

On a quarterly basis, revenue was KRW 28.7 billion in Q3 2025, KRW 27.8 billion in Q4 2025 (down 3.0% quarter on quarter), KRW 29.9 billion in Q1 2026 (up 7.5%), KRW 35.5 billion in Q2 2026 (up 18.8%) and KRW 33.9 billion in Q3 2026 (down 4.5%, but up 18.3% year on year).

Operating profit was KRW 1.12 billion in Q3 2025, KRW 2.11 billion in Q4 2025 (up 88.6%), KRW 2.08 billion in Q1 2026 (down 1.5%), KRW 3.82 billion in Q2 2026 (up 83.8%) and KRW 3.24 billion in Q3 2026 (down 15.3%, but up 189.3% year on year).

Net profit attributable to controlling shareholders fell 53.0% quarter on quarter to KRW 1.43 billion in Q3 2026, and the four quarters from Q4 2025 to Q3 2026 total KRW 8.79 billion.

According to press reports, first-half 2025 revenue was KRW 60.4 billion and operating profit KRW 7.7 billion, broadly consistent with the annual figure less the Q3 and Q4 2025 quarters.

05

Industry analysis

Demand for personal care ingredients moves with production volumes of shampoo, conditioner and skincare products, as well as the overseas expansion of cosmetics brands. Press reports from the first half of 2025 said the personal care industry is growing rapidly and new emerging markets are forming.

Because the company has a high share of overseas revenue, this trend links directly to its results. Surfactants are used in small amounts per product, so the market is not large, but according to the credit rating report competition intensity is relatively low.

The same report explained that revenue scale fluctuates with end-market conditions, selling price adjustments following raw material price moves, and global supply and demand.

Unlike large petrochemical companies in the same chemical sector, whose results swing sharply with raw material price cycles, the company sits closer to consumer demand for cosmetic ingredients. In an industry comparison from a company information site, its operating margin was shown above the chemical sector average.

The position in the industry cycle is hard to pin down with figures, and the decline in Q3 2026 after the Q2 2026 revenue peak is the near-term pattern. On the weak side, a change in surfactant prices or demand could move margins quickly.

On the strong side, the fast-growing personal care market and demand for high-function ingredients may provide a medium-term demand base.

06

Outlook

Q2 2026 revenue of KRW 35.5 billion and operating profit of KRW 3.82 billion are the largest of the last five quarters on a disclosed basis.

In Q3 2026, revenue fell to KRW 33.9 billion and operating profit to KRW 3.24 billion, both down from the prior quarter, while operating profit still rose 189.3% year on year, so the recovery trend continues.

The next checkpoints are whether Q4 2026 revenue holds near the Q3 level and whether the quarterly operating margin exceeds the 9.3% annual margin for 2025. The 2025 annual results were disclosed on January 22, 2026, so the 2026 annual preliminary results are likely to come around late January 2027.

The 2026 annual report is due by March 31, 2027, when full-year revenue and operating cash flow will be fixed in the regulatory filing. On technology, the company said in April 2025 that it would accelerate development of high-function ingredients based on dermatological science.

On the group side, whether joint proposals with affiliate Verdant lead to wider overseas customer adoption is an item to watch. On shareholder returns, the board approved in March 2026 the cancellation of 509,800 treasury shares, with a planned cancellation amount of about KRW 4.2 billion.

On governance, according to NICE Credit Rating data cited by a job site, the CEO changed from Lee Jin-yong to Ahn Tae-hwan in March 2026, so continuity of management is an item to confirm.

07

Valuation

PER
6.0×
PBR
0.4×
ROE
7.0%
EPS
₩817
BPS
₩12,030
Dividend per share
₩250

When reading the multiple, it fits the earnings trend better to view it alongside the four-quarter total of KRW 8.79 billion in net profit attributable to controlling shareholders from Q4 2025 to Q3 2026.

Net profit attributable to controlling shareholders was KRW 9.74 billion in 2025, down from KRW 17.8 billion in 2022, so the multiple is sensitive to the pace of earnings recovery. The price-to-book ratio sits below 1x, meaning the share price is below book value per share.

The dividend yield is shown above the chemical sector average on a company information site, but dividend capacity should be read together with earnings and operating cash flow, which turned negative in 2025.

Treasury share cancellation reduces the total number of shares outstanding and therefore affects per-share metrics, so it should be checked at each disclosure update. Because the same share price implies very different multiples as earnings change, the multiple level is best read alongside the direction of earnings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Export-centred global position

A credit rating report describes the company as holding the second position in the global cationic surfactant market. Press reports put exports at about 83% of first-half 2025 revenue, which is cited as a structure that benefits from overseas demand.

High-function ingredients such as the Encapguard series widen the technical consultation channel with global brands.

Quarterly profit recovery in 2026

Operating profit rose 83.8% quarter on quarter to KRW 3.82 billion in Q2 2026. Q3 2026 operating profit of KRW 3.24 billion was up 189.3% year on year, and Q3 revenue of KRW 33.9 billion was up 18.3% from a year earlier. The improved direction of quarterly profit relative to Q3 2025 is cited as the basis for the bullish case.

Low leverage and shareholder return steps

Total liabilities at the end of 2025 were KRW 18.7 billion, smaller than total equity of KRW 125.5 billion, and the debt-to-equity ratio was 14.9% in 2025. The board's decision to cancel treasury shares reduces the number of shares outstanding, which is cited as a shareholder-return fact.

A balance sheet with ample financial room is cited as a factor that could support continued dividend and treasury share policies.

09

Bear factors

Declining profit margins

The operating margin fell from 20.0% in 2022 to 9.3% in 2025. Operating profit was KRW 10.9 billion in 2025, down 27.5% from the prior year, as revenue rose 6.0% but profit did not follow. The margin recovered to 13.6% in 2024 before falling back, and this non-linear path is the core of the bearish case.

Gap between earnings and cash flow

Operating cash flow turned from KRW 24.3 billion in 2024 to -KRW 894 million in 2025. Net profit attributable to controlling shareholders was KRW 9.74 billion in the same year. The widened gap between reported earnings and cash generation is cited as a bearish factor.

Weaker Q3 2026 quarterly profit

Q3 2026 revenue of KRW 33.9 billion fell 4.5% quarter on quarter, and operating profit of KRW 3.24 billion fell 15.3%. Net profit attributable to controlling shareholders of KRW 1.43 billion fell 53.0% from the prior quarter, which shows quarterly earnings remain volatile.

The four-quarter total of KRW 8.79 billion in net profit attributable to controlling shareholders is modest in scale.

10

Risk factors

Export dependence and overseas demand

With exports reported at about 83% of first-half 2025 revenue, orders from overseas customers and changes in global brands' product strategies directly affect sales. Whether customer discussions at trade shows turn into actual orders needs to be tracked through quarterly revenue. Because of the high overseas share, changes in demand can reach reported results quickly.

Raw material and selling price swings

The credit rating report says revenue scale changes with selling price adjustments following raw material price moves and with global supply and demand conditions. Revenue rose in 2025 while operating profit fell, which suggests that the split between costs and selling prices affected the margin. If the ability to adjust prices weakens, margins could fall even at the same revenue level.

Governance and management continuity

According to NICE Credit Rating data cited by a job site, the CEO changed from Lee Jin-yong to Ahn Tae-hwan in March 2026. The largest shareholder changed to Samyang Corporation in 2017, so the ownership structure has shifted since the company joined the group. How business direction and management continue through group brand integration needs to be confirmed.

11

What to watch next

  1. Late January 2027

    Preliminary Q4 and full-year 2026 results. The 2025 annual results were disclosed on January 22, 2026, so the full-year operating margin (9.3% in 2025) and the Q4 revenue trend are the next checkpoints.

  2. By March 31, 2027

    Deadline for the 2026 annual report. Full-year revenue, operating profit and operating cash flow will be fixed in the regulatory filing, providing evidence on whether the 2025 negative operating cash flow was temporary.

  3. By May 15, 2027

    Deadline for the Q1 2027 quarterly report. This is where to check whether net profit attributable to controlling shareholders recovers from KRW 1.43 billion in Q3 2026 and whether the quarterly operating margin holds.

12

Overall view

Samyang KCI is a personal care ingredient maker centred on cationic surfactants and polymers, with a high overseas revenue share and a reported second position in the global cationic surfactant market.

Full-year 2025 revenue of KRW 116.8 billion was the largest of 2022–2025, but operating profit fell 27.5% to KRW 10.9 billion and the operating margin of 9.3% sits below 20.0% in 2022.

Quarterly operating profit rose sharply in Q2 and Q3 2026, showing a recovery, but Q3 revenue and profit both declined from the prior quarter, and the four-quarter total of net profit attributable to controlling shareholders is KRW 8.79 billion.

The swing of 2025 operating cash flow to -KRW 894 million is a bearish factor, reflecting the gap between earnings and cash generation.

On the financial side, total liabilities of KRW 18.7 billion against equity of KRW 125.5 billion at the end of 2025 indicate a light debt burden, and the March 2026 treasury share cancellation is cited as a shareholder return step.

The next checkpoints are the preliminary 2026 full-year results around late January 2027 and the 2026 annual report due by March 31, 2027. This report does not present an investment opinion, rating or target price, and its figures are based on disclosed results and press reports.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.saramin.co.kr
  2. catch.co.kr
  3. youtube.com
  4. cosinkorea.com
  5. cosmorning.com
  6. news.nate.com
  7. m.news.nate.com
  8. jobplanet.co.kr
  9. kpinews.kr
  10. news.nate.com
  11. alphasquare.co.kr
  12. saramin.co.kr
  13. samyangcorp.com
  14. m.samyangspecialty.com
  15. jasoseol.com
  16. kisrating.com
  17. news.nate.com
  18. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis